Investor Relations
Stock Information
| Ticker | SNTS |
| Exchange | NASDAQ |
| Price | $4.50 |
| Change | - 0.06 |
| Volume | 248,100 |
| Feb 22, 2012 4:00 PM ET | |
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on FENOGLIDE® (fenofibrate) Tablets, which is indicated as an adjunct to diet to reduce high cholesterol.
Santarus also has a diverse development pipeline, including three investigational drugs in late-stage clinical development: UCERIS™ (budesonide) Tablets for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers’ diarrhea, in addition to other earlier-stage development programs.
Recent Releases
Feb 22, 2012
Santarus and Depomed Announce Settlement with Lupin of GLUMETZA Patent Litigation
Feb 14, 2012
Santarus Increases Revolving Line of Credit to $35 Million and Extends Maturity to February 2015
Events & Presentations
There are no upcoming events at this time.
